ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Execs Sell Big, One CEO Bets $50M on His Own Stock

By ORTEX News · Edited by , Editor, ORTEX News1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

A sharp split in executive conviction emerged this week. Some C-suite leaders dumped tens of millions in shares. One chairman-CEO did the opposite — and went all in.

Summit Therapeutics CEO Robert Duggan filed on June 12 showing he bought $50M of SMMT stock at $13.12 per share. That's 3.8 million shares added to his position. Duggan has a history of large personal bets on his own companies.

The biggest seller this week was the Walton Family Holdings Trust. It filed June 18, disclosing it sold $467M of WMT shares on June 16. The Walton family routinely trims its stake, but this transaction stands out for size.

Applied Materials CEO Gary Dickerson filed 11 separate sell transactions. Combined, they total roughly $49M. All trades happened June 15–16. The stock recently traded near $591, close to multi-year highs. The filings appeared June 17.

DaVita CEO Javier Rodriguez also sold. He filed June 17, reporting two sales totalling $14.5M at around $209 per share.

On the buying side, a board-level investor at FUN (Six Flags Entertainment) filed two purchases totalling nearly $5.9M across June 12 and 15. FBIN (Fortune Brands Innovations) saw a hedge fund director buy $13M worth of shares on June 10, a sign of activist interest.

WGS (GeneDx Holdings) drew insider buying too. Casdin Capital filed $11.1M in purchases over two transactions, signalling institutional confidence in the genomics firm.

This article is not financial advice.

Stocks in this article

How this article was generated

Generated
21 Jun 2026, 04:14
Prompt version
v1.0
Data sources
Institutional positioning

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.